Emerging Therapies in the Evolving Biologic Platform for Psoriasis Treatment

Abstract

38 PRACTICAL DERMATOLOGY MAY 2014 I n the last decade, biologic therapy has emerged as a critical treatment modality for moderate to severe psoriasis. During that time, long-term studies for have confirmed the safety profiles for TNF inhibitors such as such as etanercept (Enbrel, Amgen) and adalimumab (Humira, AbbVie). More recently, discoveries involving various interleukin (IL) pathways have led to the development of several new agents, notably the IL-12/23 inhibitor ustekinumab (Stelara, Janssen). This has led to a flurry of new activity in the biologic pipeline for psoriasis treatment. Ahead, I will examine the latest advances in the growing treatment armamentarium and offer a glimpse of what the psoriasis treatment arena may look like in coming years.

Cite this paper

@inproceedings{Bagel2014EmergingTI, title={Emerging Therapies in the Evolving Biologic Platform for Psoriasis Treatment}, author={Jerry Bagel}, year={2014} }